2019 Innovation to Commercialization award recipients

The Innovation to Commercialization (I2C) Program is designed to help researchers advance discoveries or inventions towards commercialization by supporting commercialization activities that strengthen the value of their intellectual property, facilitate collaboration and attract future investment.

Now in its third year, MSFHR is pleased to announce nine successful award recipients for the 2019 competition. These researchers are advancing health innovations that range from new nanomedicines for type 2 diabetes; developing a safe and effective analgesic for chronic pain relief, and a smart multifunctional wound dressing for continuous monitoring and treatment of chronic injuries.

Researcher
(Host institution)
Project summary Research location
Harry Brumer
UBC
A GlycoCaged drug delivery system to improve the treatment of inflammatory bowel disease UBC (Vancouver)
Deanna Gibson
UBC
Novel bioengineered probiotics increase colonization and persistence in the gut enhancing bioavailability and their therapeutic potential for inflammatory bowel disease UBC (Okanagan)
Kenneth Harder
UBC
Improving cancer immunotherapy using G-CSF-blocking antibodies to overcome myeloid cell-mediated immunosuppression UBC (Vancouver)
Shyh-Dar Li
UBC
Developing a safe and effective analgesic for chronic pain relief UBC 
Bruce Verchere
UBC
Novel nanomedicines for resolving inflammation as a treatment for type 2 diabetes BCHRI
Mohsen Akbari
UVic
A smart multifunctional wound dressing for continuous monitoring and treatment of chronic injuries UVic 
Hongshen Ma
UBC
Technology for image-based screening to enhance protein production UBC (Vancouver)
Donald Sin
UBC
Biomarker tests to diagnose and prognose acute exacerbations of chronic obstructive pulmonary disease UBC
Stephanie Willerth
UVic
3D bioprinting personalized neural tissues for drug screening (partnered with the Pacific Parkinson's Research Institute) UVic